162 related articles for article (PubMed ID: 37983610)
1. IGF2BP2 Drives Cell Cycle Progression in Triple-Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process.
Xia T; Dai XY; Sang MY; Zhang X; Xu F; Wu J; Shi L; Wei JF; Ding Q
Adv Sci (Weinh); 2024 Jan; 11(1):e2305142. PubMed ID: 37983610
[TBL] [Abstract][Full Text] [Related]
2. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
[TBL] [Abstract][Full Text] [Related]
3. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
[TBL] [Abstract][Full Text] [Related]
4. The m6A reader IGF2BP2 promotes esophageal cell carcinoma progression by enhancing EIF4A1 translation.
Li Y; Xiao Z; Wang Y; Zhang D; Chen Z
Cancer Cell Int; 2024 May; 24(1):162. PubMed ID: 38724996
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of long non-coding RNA HOST2 inhibits the proliferation of triple negative breast cancer via regulation of the let-7b/CDK6 axis.
Zhang Y; Zhang H; Kang H; Huo W; Zhou Y; Zhang Y
Int J Mol Med; 2019 Feb; 43(2):1049-1057. PubMed ID: 30483747
[TBL] [Abstract][Full Text] [Related]
6. IGF2BP2 knockdown suppresses thyroid cancer progression by reducing the expression of long non-coding RNA HAGLR.
Dong L; Geng Z; Liu Z; Tao M; Pan M; Lu X
Pathol Res Pract; 2021 Sep; 225():153550. PubMed ID: 34340128
[TBL] [Abstract][Full Text] [Related]
7. IGF2BP2 promotes the progression of ovarian endometriosis by regulating m6A-modified MEIS2 and GATA6.
Zhao S; Zhang B; Yuan H; Yin Y; Qi S; Li W; Wu X; Yaling F
Int J Biochem Cell Biol; 2022 Nov; 152():106296. PubMed ID: 36113831
[TBL] [Abstract][Full Text] [Related]
8. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
[TBL] [Abstract][Full Text] [Related]
9. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
Yi J; Peng F; Zhao J; Gong X
Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-κB pathways.
Xiao K; Liu P; Yan P; Liu Y; Song L; Liu Y; Xie L
Bioengineered; 2022 May; 13(5):11973-11986. PubMed ID: 34709120
[TBL] [Abstract][Full Text] [Related]
11. IGF2BP2 promotes pancreatic carcinoma progression by enhancing the stability of B3GNT6 mRNA via m6A methylation.
Cao P; Wu Y; Sun D; Zhang W; Qiu J; Tang Z; Xue X; Qin L
Cancer Med; 2023 Feb; 12(4):4405-4420. PubMed ID: 35908253
[TBL] [Abstract][Full Text] [Related]
12. ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis.
Zhang X; Mu X; Huang O; Wang Z; Chen J; Chen D; Wang G
BMC Cancer; 2022 Mar; 22(1):226. PubMed ID: 35236318
[TBL] [Abstract][Full Text] [Related]
13. m6A reader IGF2BP2 promotes lymphatic metastasis by stabilizing DPP4 in papillary thyroid carcinoma.
Wang W; Ding Y; Zhao Y; Li X
Cancer Gene Ther; 2024 Feb; 31(2):285-299. PubMed ID: 38102465
[TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis.
Peng WX; Liu F; Jiang JH; Yuan H; Zhang Z; Yang L; Mo YY
Genes Dis; 2023 Mar; 10(2):554-567. PubMed ID: 37223505
[TBL] [Abstract][Full Text] [Related]
15. IGF2BP2 Regulates MALAT1 by Serving as an N6-Methyladenosine Reader to Promote NSCLC Proliferation.
Han L; Lei G; Chen Z; Zhang Y; Huang C; Chen W
Front Mol Biosci; 2021; 8():780089. PubMed ID: 35111811
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of comprehensive typing based on m6A and gene cluster in TNBC.
Wu H; Feng J; Wu J; Zhong W; Zouxu X; Huang W; Huang X; Yi J; Wang X
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4367-4380. PubMed ID: 36109402
[TBL] [Abstract][Full Text] [Related]
17. IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism.
Pu J; Wang J; Qin Z; Wang A; Zhang Y; Wu X; Wu Y; Li W; Xu Z; Lu Y; Tang Q; Wei H
Front Oncol; 2020; 10():578816. PubMed ID: 33224879
[TBL] [Abstract][Full Text] [Related]
18. A1BG-AS1 promotes adriamycin resistance of breast cancer by recruiting IGF2BP2 to upregulate ABCB1 in an m6A-dependent manner.
Wang J; Xu J; Zheng J
Sci Rep; 2023 Nov; 13(1):20730. PubMed ID: 38007504
[TBL] [Abstract][Full Text] [Related]
19. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
Hu Y; Chen J; Liu M; Feng Q; Peng H
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
[TBL] [Abstract][Full Text] [Related]
20. IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader.
Hu X; Peng WX; Zhou H; Jiang J; Zhou X; Huang D; Mo YY; Yang L
Cell Death Differ; 2020 Jun; 27(6):1782-1794. PubMed ID: 31804607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
